CoChat

Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation

Open access
Zhang, Ning, Sun, Linmao, Zhou, Shuo, Ji, Changyong, Cui, Tianming, Chu, Qi, Ye, Jiareng, Liang, Shuhang, Ma, Kun, Liu, Yufeng, Li, Xianying, Guo, Xinyu, Zhang, Weizhi, Gu, Xuetian, Cheng, Cheng, Zha, Qingrui, Tao, Shengwei, Zhang, Yunguang, Chu, Junhui, Wu, Chenghui, Zhang, Yuchen, Wang, Jiabei, Liu, Yao, Liu, Lianxin · 2025 · Nature Communications

The DOI matches its Crossref record; 78 of the 81 references it cites were found in a registry or an index.

Abstract

Gemcitabine combined with cisplatin is the first-line chemotherapy for advanced cholangiocarcinoma, but drug resistance remains a challenge, leading to unsatisfactory therapeutic effect. Here, we elucidate the possibility of chemotherapy regimens sensitized by inhibiting succinylation in patients with cholangiocarcinoma from the perspective of post-translational modification. Our omics analysis reveals that succinylation of PDHA1 lysine 83, a key enzyme in the tricarboxylic acid cycle, alters PDH enzyme activity, modulates metabolic flux, and leads to alpha-ketoglutaric acid accumulation in the tumor microenvironment. This process activates the OXGR1 receptor on macrophages, triggering MAPK signaling and inhibiting MHC-II antigen presentation, which promotes immune escape and tumor progression. Moreover, we show that inhibiting PDHA1 succinylation with CPI-613 enhances the efficacy of gemcitabine and cisplatin. Targeting PDHA1 succinylation may be a promising strategy to improve treatment outcomes in cholangiocarcinoma and warrants further clinical exploration. Succinylation, a posttranslational modification on lysine residues, is involved in tumor progression. Here, authors show that PDHA1 K83 succinylation is involved in cholangiocarcinoma tumorigenesis through regulation of macrophage antigen presentation in the tumor microenvironment

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-58429-7

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PDHA1 K83 is highly succinylated in cholangiocarcinoma and closely related to survival. a Upregulated genes revealed by succinylation proteomic analysis of cholangiocarcinoma and adjacent non-tumor tissues (n = 10). b Mass spectrometry identified the succinylation modification site K83 on PDHA1. c Quantification of PDHA1 K83Succ immunostaining performed to compare paired samples (n = 74). d Kaplan–Meier analysis of OS curves based on PDHA1 K83Succ expression. PDHA1 K83Succ expression associated with poor prognosis in CCA patients. e Representative immunofluorescence staining of CCA and adjacent normal tissues (n = 7). PDHA1 K83Succ (Red), DAPI (Blue). And statistical chart of PDHA1 K83Succ mean gray values. Scale bars: 50 μm. f Schematic illustrating transposon- and CRISPR-Cas9-(p53)-based injection of vectors into mice via the tail vein to generate tumors resembling human CCA. The transposon-based vector overexpressing KrasG12D can express luciferase. Created in BioRender. Zhang, N. (2025) https://BioRender.com/y78d999. Bioluminescence images and signal of C57BL/6 mice after plasmid injection on day 7 and day 28 (n = 10 biologically independent samples). g Front and back representative images of livers from (f). Scale bars: 1 cm. h Kaplan–Meier survival curve of C57BL/6 mice treated as in (f). i Tumor incidence of C57BL/6 mice treated as in (f). j Schematic illustrating transposon- and CRISPR-Cas9-(Pten)-based injection of vectors into mice via the tail vein to generate tumors resembling human CCA. The transposon-based vector overexpressing KrasG12D can express luciferase. Created in BioRender. Zhang, N. (2025) https://BioRender.com/j69i397. Bioluminescence images and signal of C57BL/6 mice after plasmid injection on day 7 and day 28 (n = 8 biologically independent samples). k Front and back representative images of livers from (j). Scale bars: 1 cm. l Kaplan–Meier survival curve of C57BL/6 mice treated as in (j). m Tumor incidence of C57BL/6 mice treated as in (j). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests (c, e, f, j) or log-rank test (d, h, l). HR hazard ratio, WT wild type. Source data are provided as a Source Data File.
Fig. 1 PDHA1 K83 is highly succinylated in cholangiocarcinoma and closely related to survival. a Upregulated genes revealed by succinylation proteomic analysis of cholangiocarcinoma and adjacent non-tumor tissues (n = 10). b Mass spectrometry identified the succinylation modification site K83 on PDHA1. c Quantification of PDHA1 K83Succ immunostaining performed to compare paired samples (n = 74). d Kaplan–Meier analysis of OS curves based on PDHA1 K83Succ expression. PDHA1 K83Succ expression associated with poor prognosis in CCA patients. e Representative immunofluorescence staining of CCA and adjacent normal tissues (n = 7). PDHA1 K83Succ (Red), DAPI (Blue). And statistical chart of PDHA1 K83Succ mean gray values. Scale bars: 50 μm. f Schematic illustrating transposon- and CRISPR-Cas9-(p53)-based injection of vectors into mice via the tail vein to generate tumors resembling human CCA. The transposon-based vector overexpressing KrasG12D can express luciferase. Created in BioRender. Zhang, N. (2025) https://BioRender.com/y78d999. Bioluminescence images and signal of C57BL/6 mice after plasmid injection on day 7 and day 28 (n = 10 biologically independent samples). g Front and back representative images of livers from (f). Scale bars: 1 cm. h Kaplan–Meier survival curve of C57BL/6 mice treated as in (f). i Tumor incidence of C57BL/6 mice treated as in (f). j Schematic illustrating transposon- and CRISPR-Cas9-(Pten)-based injection of vectors into mice via the tail vein to generate tumors resembling human CCA. The transposon-based vector overexpressing KrasG12D can express luciferase. Created in BioRender. Zhang, N. (2025) https://BioRender.com/j69i397. Bioluminescence images and signal of C57BL/6 mice after plasmid injection on day 7 and day 28 (n = 8 biologically independent samples). k Front and back representative images of livers from (j). Scale bars: 1 cm. l Kaplan–Meier survival curve of C57BL/6 mice treated as in (j). m Tumor incidence of C57BL/6 mice treated as in (j). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests (c, e, f, j) or log-rank test (d, h, l). HR hazard ratio, WT wild type. Source data are provided as a Source Data File.CC BY-NC-ND · PubMed Central
Fig. 2 Single-cell and Bulk RNA-seq analyses together reveal that PDHA1 K83 succinylation inhibits macrophage antigen presentation function. a tSNE (t-Distributed Stochastic Neighbor Embedding) plots of 15,830 high-quality single cells from spontaneous cholangiocarcinoma mice. b Heatmaps displaying marker genes for each cell type. c Histogram showing the proportion histogram of the eight major subtypes WT (left) and K83R (right). d tSNE plots of five different macrophage subgroups. e Dot plots showing the expression of marker genes for each cell type. f Quantitative RT-PCR analysis of mRNA levels of Cd74, H2-Ab1, H2-Aa, Cxcl9, Cxcl10 changes from PDHA1 WT or PDHA1 K83R spontaneous cholangiocarcinoma mouse tumors isolated CD45+CD11b+F4/80+ macrophages (n = 3 biologically independent samples). g Flow cytometry analysis of CD45+CD11b+F4/80+MHCII+ cells expression in mice with PDHA1 WT or PDHA1 K83R after hydrodynamic tail vein injection (n = 5 biologically independent samples). h Representative mIHC staining of spontaneous cholangiocarcinoma mouse tumors. MHCII (Red), CD86 (Green), PDHA1 K83Succ (Yellow) and DAPI (Blue). Scale bars: 20 μm. i Quantification of PDHA1 K83Succ+ and CD86+MHCII+ cells in PDHA1 WT and PDHA1 K83R spontaneous cholangiocarcinoma mouse tumors (n = 5 biologically independent samples). j Representative mIHC staining of human CCA samples using antibodies against HLA-DR (Red), CD86 (Green), PDHA1 K83Succ (Yellow) and DAPI (Blue). Scale bars: 20 μm. k Pearson correlation between the levels of PDHA1 K83Succ+ and CD86+HLA-DR+ in human CCA samples (n = 20). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests (f, g, i) or two-tailed correlation (k). Mat matrix, Macro macrophages, WT wild type. RNA-seq data is in the Genome Sequence Archive database and source data are provided as a Source Data File.
Fig. 2 Single-cell and Bulk RNA-seq analyses together reveal that PDHA1 K83 succinylation inhibits macrophage antigen presentation function. a tSNE (t-Distributed Stochastic Neighbor Embedding) plots of 15,830 high-quality single cells from spontaneous cholangiocarcinoma mice. b Heatmaps displaying marker genes for each cell type. c Histogram showing the proportion histogram of the eight major subtypes WT (left) and K83R (right). d tSNE plots of five different macrophage subgroups. e Dot plots showing the expression of marker genes for each cell type. f Quantitative RT-PCR analysis of mRNA levels of Cd74, H2-Ab1, H2-Aa, Cxcl9, Cxcl10 changes from PDHA1 WT or PDHA1 K83R spontaneous cholangiocarcinoma mouse tumors isolated CD45+CD11b+F4/80+ macrophages (n = 3 biologically independent samples). g Flow cytometry analysis of CD45+CD11b+F4/80+MHCII+ cells expression in mice with PDHA1 WT or PDHA1 K83R after hydrodynamic tail vein injection (n = 5 biologically independent samples). h Representative mIHC staining of spontaneous cholangiocarcinoma mouse tumors. MHCII (Red), CD86 (Green), PDHA1 K83Succ (Yellow) and DAPI (Blue). Scale bars: 20 μm. i Quantification of PDHA1 K83Succ+ and CD86+MHCII+ cells in PDHA1 WT and PDHA1 K83R spontaneous cholangiocarcinoma mouse tumors (n = 5 biologically independent samples). j Representative mIHC staining of human CCA samples using antibodies against HLA-DR (Red), CD86 (Green), PDHA1 K83Succ (Yellow) and DAPI (Blue). Scale bars: 20 μm. k Pearson correlation between the levels of PDHA1 K83Succ+ and CD86+HLA-DR+ in human CCA samples (n = 20). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests (f, g, i) or two-tailed correlation (k). Mat matrix, Macro macrophages, WT wild type. RNA-seq data is in the Genome Sequence Archive database and source data are provided as a Source Data File.CC BY-NC-ND · PubMed Central
Fig. 3 PDHA1 K83 succinylation modification increases α-KG in the tumor microenvironment. a Schematic diagram of THP-1 macrophages and cholangiocarcinoma cells co-culture. Created in BioRender. Zhang, N. (2025) https://BioRender.com/c42h873. After 24 h, macrophages were used for flow analysis, and CM was used for metabolite detection (n = 5 biological replicates). b Flow cytometry analysis of HLA-DR+ MFI values after co-culturing THP-1 and the CM of QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT or PDHA1 K83R after 24 h (n = 5 biological replicates). c Heatmap representing metabolite changes in tumor WT CM compared with K83 CM was obtained after 24 h culture of tumor cells (n = 5 biological replicates). d Schematic diagram of the TCA cycle metabolism in cancer. e Metabolite secretion of TCA cycle metabolic substrates α-KG, succinate, fumarate, malate and citrate changes in CM from QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT or PDHA1 K83R. Analysis was performed after 24 h (n = 5 biological replicates). f Flow cytometry analysis of HLA-DR+ MFI values of THP-1 in co-culture with tumor CM. Analysis was performed after 24 h (n = 5 biological replicates). g PDH enzyme activity of QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT and PDHA1 K83R (n = 5 biological replicates). Activity is represented as the rate in ΔOD/min. h Western blot analysis showed the expression of PDHA1 pS293, PDHA1 K83Succ changes in QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT, PDHA1 K83R, PDHA1 S293A and PDHA1 K83R S293A. The samples derive from the same experiment but different gels for PDHA1 pS293, PDHA1 K83Succ, PDHA1 and α-Tubulin were processed in parallel. The experiment was repeated three times with similar results. i PDH enzyme activity of QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT, PDHA1 K83R, PDHA1 S293A and PDHA1 K83R S293A (n = 5 biological replicates). Activity is represented as the rate in ΔOD/min. j CM α-KG concentration of QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT, PDHA1 K83R, PDHA1 S293A and PDHA1 K83R S293A (n = 5 biological replicates). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests. Mac macrophages, CM conditioned medium, MFI mean fluorescence intensity. Source data are provided as a Source Data File.
Fig. 3 PDHA1 K83 succinylation modification increases α-KG in the tumor microenvironment. a Schematic diagram of THP-1 macrophages and cholangiocarcinoma cells co-culture. Created in BioRender. Zhang, N. (2025) https://BioRender.com/c42h873. After 24 h, macrophages were used for flow analysis, and CM was used for metabolite detection (n = 5 biological replicates). b Flow cytometry analysis of HLA-DR+ MFI values after co-culturing THP-1 and the CM of QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT or PDHA1 K83R after 24 h (n = 5 biological replicates). c Heatmap representing metabolite changes in tumor WT CM compared with K83 CM was obtained after 24 h culture of tumor cells (n = 5 biological replicates). d Schematic diagram of the TCA cycle metabolism in cancer. e Metabolite secretion of TCA cycle metabolic substrates α-KG, succinate, fumarate, malate and citrate changes in CM from QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT or PDHA1 K83R. Analysis was performed after 24 h (n = 5 biological replicates). f Flow cytometry analysis of HLA-DR+ MFI values of THP-1 in co-culture with tumor CM. Analysis was performed after 24 h (n = 5 biological replicates). g PDH enzyme activity of QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT and PDHA1 K83R (n = 5 biological replicates). Activity is represented as the rate in ΔOD/min. h Western blot analysis showed the expression of PDHA1 pS293, PDHA1 K83Succ changes in QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT, PDHA1 K83R, PDHA1 S293A and PDHA1 K83R S293A. The samples derive from the same experiment but different gels for PDHA1 pS293, PDHA1 K83Succ, PDHA1 and α-Tubulin were processed in parallel. The experiment was repeated three times with similar results. i PDH enzyme activity of QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT, PDHA1 K83R, PDHA1 S293A and PDHA1 K83R S293A (n = 5 biological replicates). Activity is represented as the rate in ΔOD/min. j CM α-KG concentration of QBC939 sgPDHA1 with reconstituted expression of PDHA1 WT, PDHA1 K83R, PDHA1 S293A and PDHA1 K83R S293A (n = 5 biological replicates). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests. Mac macrophages, CM conditioned medium, MFI mean fluorescence intensity. Source data are provided as a Source Data File.CC BY-NC-ND · PubMed Central
Fig. 4 α-KG-OXGR1-MAPK signaling pathway inhibits macrophage antigen presentation function. a Gene Ontology (GO) analysis of RNA-seq after 24 h co-culture of tumor CM with or without α-KG (8 μM) and THP-1 cells. b Volcano plot to depict the downregulated HLA-DRA, HLA-DPA1, and HLA-DQA1 expression changes of immune response observed in the RNA-seq data. c Gene Set Enrichment Analysis (GSEA) indicating that positive regulation of MAPK cascade was significantly upregulated after α-KG accumulation. d Western blot analysis showed the expression of the MAPK pathway and HLA-DR, CD74 changes after 24 h co-culture (n = 3 biological replicates). The samples derive from the same experiment but different gels for p-ERK, ERK, and HLA-DR, another for CD74 and p-P38, another for p-JNK, JNK, and another for P38 and α-Tubulin were processed in parallel. e Diagram of interaction between α-KG and OXGR1 protein using molecular docking. f Western blot analysis showed the expression of p-ERK, HLA-DR, and CD74 changes after 24 h co-culture (n = 3 biological replicates). The samples derive from the same experiment but different gels for p-ERK, ERK, and HLA-DR, another for CD74, and another for OXGR1 and α-Tubulin were processed in parallel. g Schematic diagram of THP-1 with or without OXGR1 depletion and tumor CM with α-KG (0, 8 μM). Created in BioRender. Zhang, N. (2025) https://BioRender.com/a10o519. After 24 h, macrophages were used for flow analysis. h Flow cytometry analysis of HLA-DR+ MFI values from data (g) (n = 4 biological replicates). i Schematic diagram of subcutaneous tumor treatment. Created in BioRender. Zhang, N. (2025) https://BioRender.com/j80q160. And representative images of vehicle, montelukast, α-KG or combined on day 26 (n = 5 biologically independent samples). j Tumor growth of LTP-C9 with overexpression of PDHA1 WT were injected into C57BL/6 mice (n = 5 biologically independent samples), with vehicle, montelukast, α-KG or combined treatment, beginning on day 14. k Tumor volume from data (i) (n = 5 biologically independent samples). l Tumor weight from data (i) (n = 5 biologically independent samples). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests (d, f, h, k, l) or 2way ANOVA (j). Each Western blot was independently repeated three times. Mac macrophages, CM conditioned medium, MFI mean fluorescence intensity. Source data are provided as a Source Data File.
Fig. 4 α-KG-OXGR1-MAPK signaling pathway inhibits macrophage antigen presentation function. a Gene Ontology (GO) analysis of RNA-seq after 24 h co-culture of tumor CM with or without α-KG (8 μM) and THP-1 cells. b Volcano plot to depict the downregulated HLA-DRA, HLA-DPA1, and HLA-DQA1 expression changes of immune response observed in the RNA-seq data. c Gene Set Enrichment Analysis (GSEA) indicating that positive regulation of MAPK cascade was significantly upregulated after α-KG accumulation. d Western blot analysis showed the expression of the MAPK pathway and HLA-DR, CD74 changes after 24 h co-culture (n = 3 biological replicates). The samples derive from the same experiment but different gels for p-ERK, ERK, and HLA-DR, another for CD74 and p-P38, another for p-JNK, JNK, and another for P38 and α-Tubulin were processed in parallel. e Diagram of interaction between α-KG and OXGR1 protein using molecular docking. f Western blot analysis showed the expression of p-ERK, HLA-DR, and CD74 changes after 24 h co-culture (n = 3 biological replicates). The samples derive from the same experiment but different gels for p-ERK, ERK, and HLA-DR, another for CD74, and another for OXGR1 and α-Tubulin were processed in parallel. g Schematic diagram of THP-1 with or without OXGR1 depletion and tumor CM with α-KG (0, 8 μM). Created in BioRender. Zhang, N. (2025) https://BioRender.com/a10o519. After 24 h, macrophages were used for flow analysis. h Flow cytometry analysis of HLA-DR+ MFI values from data (g) (n = 4 biological replicates). i Schematic diagram of subcutaneous tumor treatment. Created in BioRender. Zhang, N. (2025) https://BioRender.com/j80q160. And representative images of vehicle, montelukast, α-KG or combined on day 26 (n = 5 biologically independent samples). j Tumor growth of LTP-C9 with overexpression of PDHA1 WT were injected into C57BL/6 mice (n = 5 biologically independent samples), with vehicle, montelukast, α-KG or combined treatment, beginning on day 14. k Tumor volume from data (i) (n = 5 biologically independent samples). l Tumor weight from data (i) (n = 5 biologically independent samples). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests (d, f, h, k, l) or 2way ANOVA (j). Each Western blot was independently repeated three times. Mac macrophages, CM conditioned medium, MFI mean fluorescence intensity. Source data are provided as a Source Data File.CC BY-NC-ND · PubMed Central
Fig. 5 DLST is the writer for PDHA1 K83 succinylation modification. a Immunofluorescence analysis to detect colocalization of PDHA1 and DLST in HCCC9810 and RBE cells. Scale bars: 20 μm. b Western blot analysis of input and anti-FLAG immunoprecipitates (IPs) derived from HEK293T cells transfected with FLAG-PDHA1 and HA-tagged EV, HAT1, KAT2A, CPT1A, DLST. The samples derive from the same experiment but different gels for Succ-K, another for HA, another for Flag, and another for α-Tubulin were processed in parallel. c Western blot analysis of input and anti-FLAG immunoprecipitates (IPs) derived from HEK293T cells transfected with FLAG-PDHA1-EV, FLAG-PDHA1 WT, FLAG-PDHA1 K83R, and HA-DLST. The samples derive from the same experiment but different gels for Succ-K, another for HA, another for Flag, and another for α-Tubulin were processed in parallel. d Western blot analysis of DLST changes from QBC939 cells. e Western blot analysis of PDHA1 K83Succ, PDHA1 pS293, PDHA1 changes from QBC939 cells after DLST depletion. The samples derive from the same experiment but different gels for PDHA1 K83Succ, PDHA1 pS293, and DLST, another for PDHA1, and another for α-Tubulin were processed in parallel. f PDH enzyme activity of QBC939 cells after DLST depletion (n = 5 biological replicates). Activity is represented as the rate in ΔOD/min. g CM α-KG concentration of QBC939 cells after DLST depletion (n = 3 biological replicates). h Flow cytometry analysis of HLA-DR+ MFI values after co-culturing the CM of QBC939 cells after DLST depletion and THP-1 after 24 h (n = 5 biological replicates). i Western blot analysis of PDHA1 pS293 and PDHA1 K83Succ changes from QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT and FLAG-PDHA1 K83R with or without DLST. The samples derive from the same experiment but different gels for PDHA1 pS293, PDHA1 K83Succ, and DLST, another for PDHA1, and another for α-Tubulin were processed in parallel. j CM α-KG concentration of QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT and Flag-PDHA1 K83R with or without DLST (n = 5 biological replicates). k Western blot analysis of PDHA1 K83Succ, PDHA1 pS293 changes from QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT cell line used CPI-613 (0, 50, 100 μM). The samples derive from the same experiment but different gels for PDHA1 K83Succ, PDHA1 pS293, another for PDHA1 and Actin were processed in parallel. l CM α-KG concentration of QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT cell line used CPI-613 (0, 50, 100 μM) (n = 5 biological replicates). m Flow cytometry analysis of HLA-DR+ MFI values after co-culturing the CM of QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT cell line used CPI-613 (0, 50, 100 μM) (n = 5 biological replicates). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests. Each Western blot was independently repeated three times. CM conditioned medium, MFI mean fluorescence intensity. Source data are provided as a Source Data File.
Fig. 5 DLST is the writer for PDHA1 K83 succinylation modification. a Immunofluorescence analysis to detect colocalization of PDHA1 and DLST in HCCC9810 and RBE cells. Scale bars: 20 μm. b Western blot analysis of input and anti-FLAG immunoprecipitates (IPs) derived from HEK293T cells transfected with FLAG-PDHA1 and HA-tagged EV, HAT1, KAT2A, CPT1A, DLST. The samples derive from the same experiment but different gels for Succ-K, another for HA, another for Flag, and another for α-Tubulin were processed in parallel. c Western blot analysis of input and anti-FLAG immunoprecipitates (IPs) derived from HEK293T cells transfected with FLAG-PDHA1-EV, FLAG-PDHA1 WT, FLAG-PDHA1 K83R, and HA-DLST. The samples derive from the same experiment but different gels for Succ-K, another for HA, another for Flag, and another for α-Tubulin were processed in parallel. d Western blot analysis of DLST changes from QBC939 cells. e Western blot analysis of PDHA1 K83Succ, PDHA1 pS293, PDHA1 changes from QBC939 cells after DLST depletion. The samples derive from the same experiment but different gels for PDHA1 K83Succ, PDHA1 pS293, and DLST, another for PDHA1, and another for α-Tubulin were processed in parallel. f PDH enzyme activity of QBC939 cells after DLST depletion (n = 5 biological replicates). Activity is represented as the rate in ΔOD/min. g CM α-KG concentration of QBC939 cells after DLST depletion (n = 3 biological replicates). h Flow cytometry analysis of HLA-DR+ MFI values after co-culturing the CM of QBC939 cells after DLST depletion and THP-1 after 24 h (n = 5 biological replicates). i Western blot analysis of PDHA1 pS293 and PDHA1 K83Succ changes from QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT and FLAG-PDHA1 K83R with or without DLST. The samples derive from the same experiment but different gels for PDHA1 pS293, PDHA1 K83Succ, and DLST, another for PDHA1, and another for α-Tubulin were processed in parallel. j CM α-KG concentration of QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT and Flag-PDHA1 K83R with or without DLST (n = 5 biological replicates). k Western blot analysis of PDHA1 K83Succ, PDHA1 pS293 changes from QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT cell line used CPI-613 (0, 50, 100 μM). The samples derive from the same experiment but different gels for PDHA1 K83Succ, PDHA1 pS293, another for PDHA1 and Actin were processed in parallel. l CM α-KG concentration of QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT cell line used CPI-613 (0, 50, 100 μM) (n = 5 biological replicates). m Flow cytometry analysis of HLA-DR+ MFI values after co-culturing the CM of QBC939 sgPDHA1 with reconstituted expression of FLAG-PDHA1 WT cell line used CPI-613 (0, 50, 100 μM) (n = 5 biological replicates). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests. Each Western blot was independently repeated three times. CM conditioned medium, MFI mean fluorescence intensity. Source data are provided as a Source Data File.CC BY-NC-ND · PubMed Central
Fig. 6 Inhibiting PDHA1 succinylation can inhibit the progression of cholangiocarcinoma. a Schematic diagram of subcutaneous tumor treatment. Created in BioRender. Zhang, N. (2025) https://BioRender.com/g40g507. b Tumor growth of LTP-C9 with overexpression of PDHA1 WT were injected into C57BL/6 mice (n = 6 biologically independent samples), with vehicle, CPI-613, Gem+Cis or combined treatment, beginning on day 14, CPI-613 and vehicle were administered daily, Gem+Cis were administered on experimental days (ED) 1, 5, 9, and 13. c Representative images of tumor volumes from vehicle, CPI-613, Gem+Cis or combined treatment on day 30 (n = 6 biologically independent samples). d Tumor volume and weight from data (b) (n = 6 biologically independent samples). e Schematic diagram of spontaneous tumor treatment. Created in BioRender. Zhang, N. (2025) https://BioRender.com/v16u276. f Bioluminescence images of C57BL/6 mice after plasmid injection on day 7, and mice on day 28 after administration of vehicle, CPI-613, Gem+Cis or combined treatment. g Bioluminescence signal from data (e) (n = 10 biologically independent samples). h Front and back representative images of livers from (e). Scale bars: 1 cm. i Kaplan–Meier survival curve of C57BL/6 mice treated as in (e) (n = 10 biologically independent samples). j Tumor incidence from data (e). k Flow cytometry analysis of CD45+CD11b+F4/80+MHCII+ cells expression of vehicle, CPI-613, Gem+Cis or combined treatment (n = 5 biologically independent samples). l Flow cytometry analysis of CD45+CD3+CD4+T cells expression of vehicle, CPI-613, Gem+Cis or combined treatment (n = 5 biologically independent samples). m Flow cytometry analysis of CD45+CD3+CD8+T cells expression of vehicle, CPI-613, Gem+Cis or combined treatment (n = 5 biologically independent samples). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests (d, g, k–m), 2way ANOVA (b) or log-rank test (i). Gem gemcitabine, Cis cisplatin. Source data are provided as a Source Data File.
Fig. 6 Inhibiting PDHA1 succinylation can inhibit the progression of cholangiocarcinoma. a Schematic diagram of subcutaneous tumor treatment. Created in BioRender. Zhang, N. (2025) https://BioRender.com/g40g507. b Tumor growth of LTP-C9 with overexpression of PDHA1 WT were injected into C57BL/6 mice (n = 6 biologically independent samples), with vehicle, CPI-613, Gem+Cis or combined treatment, beginning on day 14, CPI-613 and vehicle were administered daily, Gem+Cis were administered on experimental days (ED) 1, 5, 9, and 13. c Representative images of tumor volumes from vehicle, CPI-613, Gem+Cis or combined treatment on day 30 (n = 6 biologically independent samples). d Tumor volume and weight from data (b) (n = 6 biologically independent samples). e Schematic diagram of spontaneous tumor treatment. Created in BioRender. Zhang, N. (2025) https://BioRender.com/v16u276. f Bioluminescence images of C57BL/6 mice after plasmid injection on day 7, and mice on day 28 after administration of vehicle, CPI-613, Gem+Cis or combined treatment. g Bioluminescence signal from data (e) (n = 10 biologically independent samples). h Front and back representative images of livers from (e). Scale bars: 1 cm. i Kaplan–Meier survival curve of C57BL/6 mice treated as in (e) (n = 10 biologically independent samples). j Tumor incidence from data (e). k Flow cytometry analysis of CD45+CD11b+F4/80+MHCII+ cells expression of vehicle, CPI-613, Gem+Cis or combined treatment (n = 5 biologically independent samples). l Flow cytometry analysis of CD45+CD3+CD4+T cells expression of vehicle, CPI-613, Gem+Cis or combined treatment (n = 5 biologically independent samples). m Flow cytometry analysis of CD45+CD3+CD8+T cells expression of vehicle, CPI-613, Gem+Cis or combined treatment (n = 5 biologically independent samples). Data are presented as mean values ± SD, and P values were calculated using two-tailed unpaired Student’s t-tests (d, g, k–m), 2way ANOVA (b) or log-rank test (i). Gem gemcitabine, Cis cisplatin. Source data are provided as a Source Data File.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Research works printed but not linked: 1

  1. Wu, J. Y. et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol. Cell. 77, 213–227.e5 (2020). · DOI · Paper page

Cited by

See all 44

Metadata

Authors
Zhang, N., Sun, L., Zhou, S., Ji, C., Cui, T., Chu, Q., Ye, J., Liang, S., Ma, K., Liu, Y., Li, X., Guo, X., Zhang, W., Gu, X., Cheng, C., Zha, Q., Tao, S., Zhang, Y., Chu, J., Wu, C., Zhang, Y., Wang, J., Liu, Y., & Liu, L.
Affiliations
  • First Affiliated Hospital of Harbin Medical University (CN)
  • University of Science and Technology of China (CN)
  • Sun Yat-sen University Cancer Center (CN)
  • Jining First People's Hospital (CN)
  • Harbin Medical University (CN)
Corresponding author
  • Liu, Yufeng
  • Wang, Jiabei
Venue
Nature Communications
Published
2025-04-03
Volume
16
Issue
1
Pages
3177-3177
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4409149833
Cited by
34
References
81
Citations by year
2026: 22 · 2025: 12
FWCI
31.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (No.82102705, No. U19A2008, No. U19A2008, No.82272787, No.82373232, No.82473189, No.82303259)
Topics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
cholangiocarcinoma, PDHA1, lysine succinylation, macrophage antigen presentation, MHC class II, MAPK signaling, tumor immune evasion, CPI-613, gemcitabine, cisplatin, drug resistance, TCA cycle, tumor microenvironment, post-translational modification
MeSH terms
Gemcitabine, Animals, Bile Duct Neoplasms, Cisplatin, Deoxycytidine, Female, Humans, Ketoglutaric Acids, Macrophages, Male, Protein Processing, Post-Translational, Antigen Presentation, Cholangiocarcinoma, Cell Line, Tumor, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation. https://app.cochat.ai/papers/10.1038/s41467-025-58429-7
The paper
Zhang, N., Sun, L., Zhou, S., Ji, C., Cui, T., Chu, Q., Ye, J., Liang, S., Ma, K., Liu, Y., Li, X., Guo, X., Zhang, W., Gu, X., Cheng, C., Zha, Q., Tao, S., Zhang, Y., Chu, J., . . . Liu, L. (2025). Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation. Nature Communications. https://doi.org/10.1038/s41467-025-58429-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.